Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Effect of drug treatment options on the mobility and expression of blaKPC.

Roth AL, Lister PD, Hanson ND.

J Antimicrob Chemother. 2013 Dec;68(12):2779-85. doi: 10.1093/jac/dkt280. Epub 2013 Jul 16.

PMID:
23861308
2.

Production of KPC-2 alone does not always result in β-lactam MICs representing resistance in gram-negative pathogens.

Roth AL, Thomson KS, Lister PD, Hanson ND.

J Clin Microbiol. 2012 Dec;50(12):4183-4. doi: 10.1128/JCM.02194-12. Epub 2012 Sep 12. No abstract available.

3.

Mechanisms of β-lactam resistance among Pseudomonas aeruginosa.

Wolter DJ, Lister PD.

Curr Pharm Des. 2013;19(2):209-22. Review.

PMID:
22894618
4.

bla(KPC) RNA expression correlates with two transcriptional start sites but not always with gene copy number in four genera of Gram-negative pathogens.

Roth AL, Kurpiel PM, Lister PD, Hanson ND.

Antimicrob Agents Chemother. 2011 Aug;55(8):3936-8. doi: 10.1128/AAC.01509-10. Epub 2011 May 16.

5.

Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Lister PD, Wolter DJ, Hanson ND.

Clin Microbiol Rev. 2009 Oct;22(4):582-610. doi: 10.1128/CMR.00040-09. Review.

6.

Multiple genotypic changes in hypersusceptible strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients do not always correlate with the phenotype.

Wolter DJ, Black JA, Lister PD, Hanson ND.

J Antimicrob Chemother. 2009 Aug;64(2):294-300. doi: 10.1093/jac/dkp185. Epub 2009 May 25.

PMID:
19468029
7.

Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.

Lister PD.

Postgrad Med. 2008 Sep;120(3 Suppl 1):46-52. doi: 10.3810/pgm.2008.09.suppl52.284.

PMID:
18931471
8.

Carbapenems in the USA: focus on doripenem.

Lister PD.

Expert Rev Anti Infect Ther. 2007 Oct;5(5):793-809. Review.

PMID:
17914914
9.

Increased expression of ampC in Pseudomonas aeruginosa mutants selected with ciprofloxacin.

Wolter DJ, Schmidtke AJ, Hanson ND, Lister PD.

Antimicrob Agents Chemother. 2007 Aug;51(8):2997-3000. Epub 2007 May 21.

10.

Levofloxacin/imipenem prevents the emergence of high-level resistance among Pseudomonas aeruginosa strains already lacking susceptibility to one or both drugs.

Lister PD, Wolter DJ, Wickman PA, Reisbig MD.

J Antimicrob Chemother. 2006 May;57(5):999-1003. Epub 2006 Mar 2.

PMID:
16513915
11.

The role of pharmacodynamic research in the assessment and development of new antibacterial drugs.

Lister PD.

Biochem Pharmacol. 2006 Mar 30;71(7):1057-65. Review.

PMID:
16316633
13.
14.

Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital.

Wolter DJ, Smith-Moland E, Goering RV, Hanson ND, Lister PD.

Diagn Microbiol Infect Dis. 2004 Sep;50(1):43-50.

PMID:
15380277
15.

Insertional inactivation of oprD in clinical isolates of Pseudomonas aeruginosa leading to carbapenem resistance.

Wolter DJ, Hanson ND, Lister PD.

FEMS Microbiol Lett. 2004 Jul 1;236(1):137-43.

16.

Pharmacodynamic study of beta-lactams alone and in combination with beta-lactamase inhibitors against Pseudomonas aeruginosa possessing an inducible beta-lactamase.

Li C, Nicolau DP, Lister PD, Quintiliani R, Nightingale CH.

J Antimicrob Chemother. 2004 Feb;53(2):297-304. Epub 2004 Jan 16.

PMID:
14729755
17.
18.
19.
21.

Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.

Lister PD, Sanders CC.

J Antimicrob Chemother. 2001 Jun;47(6):811-8.

PMID:
11389113
23.
24.

Emerging resistance problems among respiratory tract pathogens.

Lister PD.

Am J Manag Care. 2000 May;6(8 Suppl):S409-18. Review.

25.

Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.

Lister PD, Sanders CC.

J Antimicrob Chemother. 1999 Jan;43(1):79-86.

PMID:
10381104
26.
28.

Cefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.

Lister PD, Sanders WE Jr, Sanders CC.

Antimicrob Agents Chemother. 1998 Jul;42(7):1610-9.

29.
32.
34.

Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections.

Lister PD.

Eur J Clin Microbiol Infect Dis. 1995;14 Suppl 1:S18-25. Review.

PMID:
7729467
35.
36.

Ethanol impairs neutrophil chemotaxis in vitro but not adherence or recruitment to lungs of rats with experimental pneumococcal pneumonia.

Lister PD, Gentry MJ, Preheim LC.

J Infect Dis. 1993 May;167(5):1131-7. Erratum in: J Infect Dis 1993 Jul;168(1):262.

PMID:
8517883
37.

Cirrhosis impairs serum bacteriostasis for Escherichia coli.

Lister PD, Mellencamp MA, Preheim LC.

J Lab Clin Med. 1992 Oct;120(4):633-8.

PMID:
1402339
38.

In vitro susceptibilities of Edwardsiella tarda to 22 antibiotics and antibiotic-beta-lactamase-inhibitor agents.

Clark RB, Lister PD, Janda JM.

Diagn Microbiol Infect Dis. 1991 Mar-Apr;14(2):173-5.

PMID:
1873976
39.

In vitro susceptibilities of Plesiomonas shigelloides to 24 antibiotics and antibiotic-beta-lactamase-inhibitor combinations.

Clark RB, Lister PD, Arneson-Rotert L, Janda JM.

Antimicrob Agents Chemother. 1990 Jan;34(1):159-60.

40.

Arthritis associated with leucocytoclastic angiitis.

Lister PD, Hollingworth P.

Ann Rheum Dis. 1980 Oct;39(5):526-7.

Supplemental Content

Loading ...
Support Center